Jump to main content
Jump to site search

Issue 4, 2016
Previous Article Next Article

Synthesis and bioactivity of antitubercular peptides and peptidomimetics: an update

Author affiliations

Abstract

Mycobacterium tuberculosis is the causative agent of tuberculosis (TB), an infection that has been declared a global public health emergency by the World Health Organization. Current anti-TB therapies are limited in their efficacy and have failed to prevent the spread of TB, due to the long term drug compliance required and the genesis of multidrug-resistant strains (MDR). The number of chemotherapeutic agents currently available to treat MDR is limited, therefore there is a great need for new anti-TB drugs. Anti-TB peptides and peptidomimetics have emerged as an important and growing class of chemotherapeutic agents. This mini-review provides an update on peptides that exhibit very potent anti-TB activity, and their chemical syntheses, which could potentially be included in the pipeline for new anti-TB drug development.

Graphical abstract: Synthesis and bioactivity of antitubercular peptides and peptidomimetics: an update

Back to tab navigation

Article information


Submitted
09 Nov 2015
Accepted
30 Nov 2015
First published
30 Nov 2015

Org. Biomol. Chem., 2016,14, 1177-1187
Article type
Review Article
Author version available

Synthesis and bioactivity of antitubercular peptides and peptidomimetics: an update

L. M. De Leon Rodriguez, H. Kaur and M. A. Brimble, Org. Biomol. Chem., 2016, 14, 1177
DOI: 10.1039/C5OB02298C

Social activity

Search articles by author

Spotlight

Advertisements